{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019674","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.095770+00:00","generated_at":"2026-06-15T08:56:04.149282+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances","bullets":["Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.","Cash, equivalents and investments $204.5M at Mar 31, 2023, versus $193.7M at Dec 31, 2022; includes $35M Moderna upfront and $5M Astellas milestone.","AbbVie terminated CD71 collaboration; CX-2029 not advanced to additional studies; CytomX evaluating full rights acquisition and next-gen CD71 strategies.","BMS advanced BMS-986288 (anti-CTLA-4 Probody) from Phase 1 to Phase 2 as lead next-gen CTLA-4 program.","Marcia Belvin promoted to Chief Scientific Officer; IND filings for CX-2051 and CX-801 targeted for H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019674","json":"https://secwatch.observer/filing/0000950170-23-019674.json","markdown":"https://secwatch.observer/filing/0000950170-23-019674.md","text":"https://secwatch.observer/filing/0000950170-23-019674.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/0000950170-23-019674-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/ctmx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:56:04.149282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5101a16341561ca8c229df097bf82c1ebfd420ad","claim":"CytomX Therapeutics, Inc. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/0000950170-23-019674-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}